testing the validity of a prognostic model for castration-resistant prostate cancer
Published 1 year ago • 294 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
33:19
castration resistant prostate cancer - developments and challenges from 2020
-
12:48
prognostic biomarker tests for prostate cancer
-
1:00:16
castration resistant prostate cancer: diagnosis & testing considerations with use of parp inhibitors
-
6:11
introduction to advanced prostate cancer (royal stage) | prostate cancer staging guide
-
13:46
timing and optimization of radium 223 in castration resistant prostate cancer
-
7:17
understanding metastatic castration-resistant prostate cancer
-
7:46
prostate cancer: validation of ar-v7 testing
-
5:04
castrate resistant prostate cancer
-
6:01
androgen receptor and castration-resistant prostate cancer
-
3:56
about metastatic castrate-resistant prostate cancer
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
4:56
improving the prognosis for patients with mcrpc
-
28:19
targeting ar in castration resistant prostate cancer
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
5:01
fda d.i.s.c.o.: a new drug approval for non-metastatic castration-resistant prostate cancer
-
8:45
clinical trials in nonmetastatic castration-resistant prostate cancer